Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam S Morgenthau

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Respiratory Medicine|October 26, 2018
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): Genuine disease entity, obscure clinical phenotype or diagnostic red herring?Adam S Morgenthau
The Lancet. Rheumatology|January 24, 2024
Targeting mTOR in sarcoid granulomas: where the rubber meets the roadAdam S Morgenthau
The Mount Sinai Journal of Medicine, New York|January 27, 2009
"End-stage" pulmonary fibrosis in sarcoidosisAlvin T Teirstein, Adam S Morgenthau
Chest|January 7, 2011
Recent advances in sarcoidosisAdam S Morgenthau, Michael C Iannuzzi
Expert Review of Respiratory Medicine|November 16, 2011
Sarcoidosis of the upper and lower airwaysAdam S Morgenthau, Alvin S Teirstein
The Mount Sinai Journal of Medicine, New York|January 27, 2009
Spectrum of fibrosing diffuse parenchymal lung diseaseAdam S Morgenthau, Maria L Padilla
Lung|September 21, 2023
Current Applications of Artificial Intelligence in SarcoidosisDana Lew, Eyal Klang, Shelly Soffer, et al.
Respiratory Medicine|December 15, 2021
Utility of electrophysiologic testing for sudden death risk stratification in cardiac sarcoidosis patients with mildly impaired left ventricular functionPranai Tandon, Tayseer Mosleh, Ali Mustafa, et al.
Current Opinion in Pulmonary Medicine|July 11, 2024
Leveraging AI technology in sarcoidosisAkiff Premjee, Lawrence Li, Srilakashmi Garikapati, et al.
Lung|September 11, 2020
Moderate or Severe Impairment in Pulmonary Function is Associated with Mortality in Sarcoidosis Patients Infected with SARS‑CoV‑2Adam S Morgenthau, Matthew A Levin, Robert Freeman, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Respiratory Medicine|October 26, 2018
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): Genuine disease entity, obscure clinical phenotype or diagnostic red herring?Adam S Morgenthau
The Lancet. Rheumatology|January 24, 2024
Targeting mTOR in sarcoid granulomas: where the rubber meets the roadAdam S Morgenthau
The Mount Sinai Journal of Medicine, New York|January 27, 2009
"End-stage" pulmonary fibrosis in sarcoidosisAlvin T Teirstein, Adam S Morgenthau
Chest|January 7, 2011
Recent advances in sarcoidosisAdam S Morgenthau, Michael C Iannuzzi
Expert Review of Respiratory Medicine|November 16, 2011
Sarcoidosis of the upper and lower airwaysAdam S Morgenthau, Alvin S Teirstein
The Mount Sinai Journal of Medicine, New York|January 27, 2009
Spectrum of fibrosing diffuse parenchymal lung diseaseAdam S Morgenthau, Maria L Padilla
Lung|September 21, 2023
Current Applications of Artificial Intelligence in SarcoidosisDana Lew, Eyal Klang, Shelly Soffer, et al.
Respiratory Medicine|December 15, 2021
Utility of electrophysiologic testing for sudden death risk stratification in cardiac sarcoidosis patients with mildly impaired left ventricular functionPranai Tandon, Tayseer Mosleh, Ali Mustafa, et al.
Current Opinion in Pulmonary Medicine|July 11, 2024
Leveraging AI technology in sarcoidosisAkiff Premjee, Lawrence Li, Srilakashmi Garikapati, et al.
Lung|September 11, 2020
Moderate or Severe Impairment in Pulmonary Function is Associated with Mortality in Sarcoidosis Patients Infected with SARS‑CoV‑2Adam S Morgenthau, Matthew A Levin, Robert Freeman, et al.
Pageof 2